B-ALL/MM/NHL
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM) Trial in Shanghai (Autologous CAR-T
Recruiting
- Acute Myeloid Leukemia (AML)
- +4 more
- Autologous CAR-T cells
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pudong Hospital, Fudan University Affiliated Pudong Med
Aug 22, 2022
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
-
Aurora, ColoradoChildren's Hospital Colorado
Nov 9, 2022
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical
Completed
- Multiple Myeloma
- +7 more
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)
Not yet recruiting
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- B-cell Acute Lymphoblastic Lymphoma (B-ALL)
- PIT565
- (no location specified)
Jun 13, 2022
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)
Recruiting
- B-Cell Leukemia
- B Cell Lymphoma
- anti-CD19 UCAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022
Relapsed or Refractory B-cell Malignancy(NHL/ALL) Trial in Luoyang (ET-02)
Recruiting
- Relapsed or Refractory B-cell Malignancy(NHL/ALL)
- ET-02
-
Luoyang, Henan, China•The First Affiliated Hospital of Henan University of Science an
Aug 26, 2021
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in United States (PBCAR0191, Fludarabine, Cyclophosphamide)
Recruiting
- Non-Hodgkin Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- PBCAR0191
- +2 more
-
Duarte, California
- +9 more
Apr 18, 2022
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Hematological Malignancies Trial in Beijing, Tianjin (TQB3820 tablets)
Recruiting
- Hematological Malignancies
- TQB3820 tablets
-
Beijing, Beijing, China
- +1 more
Sep 18, 2021
Hematological Malignancies - SANGUINE
Recruiting
- Hematologic Malignancy
- Blood sampling for HemaChip screening/diagnostic testing
- Bone marrow sampling
-
Olomouc, Czechia
- +3 more
Feb 9, 2023
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) Trial in Zhengzhou, Hangzhou (CD19-UCART)
Recruiting
- Acute Lymphoblastic Leukemia (ALL)
- Non Hodgkin Lymphoma (NHL)
- CD19-UCART
-
Zhengzhou, Henan, China
- +1 more
Apr 2, 2022
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,
Active, not recruiting
- Multiple Myeloma
- +2 more
- Tiragolumab
- +3 more
-
Denver, Colorado
- +12 more
Jan 19, 2023
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma Trial in United States (clonoSEQ
Recruiting
- Acute Lymphoblastic Leukemia, Adult B-Cell
- +3 more
- clonoSEQ Assay
-
Stanford, California
- +15 more
Jan 30, 2023
Operable Breast Cancer Trial in India (0.5% lignocaine 60mM)
Active, not recruiting
- Operable Breast Cancer
- 0.5% lignocaine 60mM
-
Guwahati, Assam, India
- +10 more
Mar 21, 2022
Multiple Myeloma, Lymphoma, Non-Hodgkin's Trial in United States (CFT7455, Dexamethasone Oral)
Recruiting
- Multiple Myeloma
- Lymphoma, Non-Hodgkin's
- CFT7455
- Dexamethasone Oral
-
Phoenix, Arizona
- +12 more
Dec 12, 2022
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,
Recruiting
- Waldenstrom Macroglobulinemia
- +8 more
- Iopofosine I 131 single dose
- +2 more
-
Redlands, California
- +42 more
Dec 30, 2022
Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)
Recruiting
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Etoposide
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Jan 25, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- Cyclophosphamide
- +2 more
-
São Paulo, BrazilHospital Israelita Albert Einstein
Jan 20, 2023
All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,
Active, not recruiting
- All Malignancies
- +11 more
- Tazemetostat
- +2 more
-
Encinitas, California
- +9 more
May 20, 2022
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL) Trial in Japan (azacitadine, venetoclax,
Completed
- Non-Hodgkin Lymphoma (NHL)
- +4 more
- azacitadine
- +2 more
-
Nagoya shi, Aichi, Japan
- +13 more
Jul 29, 2021
T-cell Lymphoblastic Lymphoma Trial in Shanghai, Chengdu (Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine,
Not yet recruiting
- T-cell Lymphoblastic Lymphoma
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
-
Shanghai, Shanghai, China
- +1 more
Dec 27, 2022
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide
Active, not recruiting
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Brexucabtagene Autoleucel (KTE-X19)
- +2 more
-
Los Angeles, California
- +30 more
Nov 2, 2022